Evidence map›Paper›PMID 35111681›Full record

ReviewFrontiers in oncology2021

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Jinjin Chu, Xianzhu Fang, Zhonghou Sun, Linlin Gai, Wenqing Dai, Haibo Li, Xinyi Yan, Jinke Du, Lili Zhang, Lu Zhao and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Circular RNAJournal of thoracic disease · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jinjin ChuCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Xianzhu FangDepartment of Pathology and Pathophysiology, Weifang Medical University, Weifang, China.
Zhonghou SunDepartment of Pediatrics of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Linlin GaiCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Wenqing DaiCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Haibo LiCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Xinyi YanCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Jinke DuCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Lili ZhangCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Lu ZhaoCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Donghua XuCentral Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China.
Shushan YanDepartment of Gastrointestinal and Anal Diseases Surgery of the Affiliated Hospital, Weifang Medical University, Weifang, China.
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third prevalent cancer worldwide, the morbidity and mortality of which have been increasing in recent years. As molecular targeting agents, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (McAbs) have significantly increased the progression-free survival (PFS) and overall survival (OS) of metastatic CRC (mCRC) patients. Nevertheless, most patients are eventually resistant to anti-EGFR McAbs. With the intensive study of the mechanism of anti-EGFR drug resistance, a variety of biomarkers and pathways have been found to participate in CRC resistance to anti-EGFR therapy. More and more studies have implicated non-coding RNAs (ncRNAs) primarily including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely involved in tumorigenesis and tumor progression. They function as essential regulators controlling the expression and function of oncogenes. Increasing data have shown ncRNAs affect the resistance of molecular targeted drugs in CRC including anti-EGFR McAbs. In this paper, we have reviewed the advance in mechanisms of ncRNAs in regulating anti-EGFR McAbs therapy resistance in CRC. It provides insight into exploring ncRNAs as new molecular targets and prognostic markers for CRC.

Indexed as

circRNACRCdrug resistanceEGFRlncRNAmiRNA

Identifiers

PMID35111681
PMCPMC8802825
OpenAlexW4206626194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.